GET DAILY SIGNALSAfya Limited (AFYA): Analyst Targets Point to +43% Upside Toward $15
Key Takeaways
- The central target of $15 is the arithmetic mean of five verified, current analyst price targets for Afya Limited, rounded from a calculated $15.12.
- At a latest verified close near $10.51, reaching $15 would require roughly a 43% rise — a substantial move from current levels.
- Analyst targets remain wide, spanning roughly $12 to $18, reflecting genuine disagreement between bullish and cautious firms.
- The strongest support comes from a low valuation (a single-digit P/E), recent Buy upgrades, and a resilient, low-leverage balance sheet.
- The biggest risks are a sharp late-2026 selloff, Morgan Stanley's Underweight rating, and Brazil's macro and currency backdrop.
- You can track the latest developments on Afya's Major News, Today's Price Move, Forecast, and Earnings pages.
- Explore Trending AI Robots to see how AI-driven tools are approaching opportunities across the market.
What Analysts Are Saying About AFYA
Afya Limited (NASDAQ: AFYA), a Brazilian medical education group, is covered by a relatively small number of sell-side firms. Reviewing five recent, individually attributed targets yields a calculated mean of about $15.12, which rounds to a central target of $15. The individual figures span roughly $12 to $18.
The views behind those numbers differ sharply. J.P. Morgan (Marcelo Santos) upgraded the stock to Buy in early October 2026 and trimmed its target to $18 in early November. Bank of America (Flavio Yoshida) upgraded Afya to Buy in late October 2026 with a $16 target, describing the selloff as "exaggerated" given a resilient student base, low leverage, and what it called an "attractive" valuation. Bradesco holds a $17 Buy target, while Citigroup set a more cautious $12 with a Buy rating. On the other side, Morgan Stanley (Mauricio Cepeda) cut its target to $12.60 and carries an Underweight rating, the clearest bearish signal in the group. This wide range — and the presence of both Buy and Underweight ratings — means the $15 central target is an average, not a prediction, and it should not be read as a published consensus. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Where AFYA Stands Today and the Road to $15
Afya shares closed near $10.51 on November 10, 2026, after a sharp late-October decline that took the stock from roughly $15 to a 52-week low of $9.66 on October 30, 2026. The shares have since stabilized just above $10. Reaching $15 would require a gain of about 43%, a substantial move for a stock of this size, and would essentially recover the ground lost in the recent selloff while remaining below the 52-week high of $16.16.
The path toward the target depends on whether investors can regain confidence in Afya's fundamentals. The company has continued to grow: unaudited first-quarter 2026 results showed revenue of R$1.01 billion and net income of R$261.8 million, up from R$936.4 million and R$257.0 million a year earlier. At current prices the stock trades at roughly 6.5 times trailing earnings per share (EPS, or profit per share), a valuation that leaves room for re-rating if growth persists. However, a return toward $15 would likely require both stabilizing investor sentiment and evidence that the late-2026 selloff was overdone rather than a signal of deeper problems.
Factors That Could Drive AFYA Higher
- Low valuation: A price-to-earnings (P/E) ratio near 6.5x is inexpensive relative to most growth-oriented education and healthcare names.
- Upgrades and target support: Recent Buy calls from J.P. Morgan, Bank of America, Bradesco, and Citigroup suggest improving sell-side sentiment even as targets were reduced.
- Resilient operations: Analysts cite a resilient student base, strong gross margins, and low leverage as reasons the selloff may have been disproportionate.
- Growth trajectory: Year-over-year revenue and earnings growth in recent quarters point to an expanding medical education franchise in Brazil.
Risks Standing in the Way
- Bearish positioning: Morgan Stanley's Underweight rating and its $12.60 target sit below the central target and signal a more cautious fundamental view.
- Recent price momentum: The stock's sharp fall and its position below major moving averages reflect damaged technical momentum that could take time to repair.
- Macro and currency risk: As a Brazil-focused company, Afya is exposed to the real's exchange rate, domestic interest rates, and the health of Brazil's education financing environment.
- Valuation compression: If earnings growth slows or guidance disappoints, even a low multiple can compress further, keeping shares well below $15.
Key Technical Levels to Watch
The 52-week low of $9.66, set on October 30, 2026, is the most important nearby support level; a break below it would leave the stock without a clear floor in recent history. On the upside, the shares now trade below both the 50-day and 200-day moving averages, and the prior consolidation zone around $12 to $13 represents the first meaningful resistance area on any recovery toward $15. The $16.16 52-week high marks the next major reference point above the central target. Until Afya reclaims and holds the $12 level, the longer-term trend structure remains tilted downward.
Looking Ahead: Key Dates and Catalysts
Analyst price targets typically reflect a research horizon of roughly 12 months, though individual firms may use different valuation dates, which is one reason targets in this set differ so much. Investors focused on the $15 objective should watch Afya's next quarterly earnings report, scheduled for November 12, 2026, along with any guidance updates, subsequent analyst revisions, Brazil's interest-rate and currency environment, and changes in student enrollment and tuition demand. Because the stock fell sharply ahead of that report, the market's reaction to results and guidance will be especially important. From what I see, this upcoming release could clarify whether the recent weakness was temporary.
Leveraging AI for Stock Monitoring
I have found Tickeron's AI Daily Buy/Sell Signals helpful for tracking names like Afya that show sharp volatility and mixed analyst views. The system uses artificial intelligence to monitor thousands of stocks and generate signals based on technical behavior and market conditions, which can support more timely position management as trends shift.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
AFYA in downward trend: 10-day moving average moved below 50-day moving average on October 28, 2026
The 10-day moving average for AFYA crossed bearishly below the 50-day moving average on October 28, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 18 of 21 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 86%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on AFYA as a result. In 60 of 81 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 74%.
The Moving Average Convergence Divergence Histogram (MACD) for AFYA turned negative on October 26, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 45 similar instances when the indicator turned negative. In 31 of the 45 cases the stock turned lower in the days that followed. This puts the odds of success at 69%.
AFYA moved below its 50-day moving average on October 26, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AFYA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 77%.
The Aroon Indicator for AFYA entered a downward trend on October 08, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where AFYA's RSI Oscillator exited the oversold zone, 23 of 28 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 82%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 46 of 54 cases where AFYA's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 85%.
Following a +5.12% 3-day Advance, the price is estimated to grow further. Considering data from situations where AFYA advanced for three days, in 214 of 286 cases, the price rose further within the following month. The odds of a continued upward trend are 75%.
AFYA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is 52 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 79 (best 1 - 100 worst), indicating slightly worse than average price growth. AFYA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 92 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.190) is normal, around the industry mean (1.158). P/E Ratio (1.203) is within average values for comparable stocks, (8.484). AFYA's Projected Growth (PEG Ratio) (5.160) is very high in comparison to the industry average of (1.327). Dividend Yield (0.500) settles around the average of (4.151) among similar stocks. P/S Ratio (1.661) is also within normal values, averaging (27.566).
The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AFYA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 87, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a medical education group in Brazil, which delivers an end-to-end physician-centric ecosystem that serves and empowers students to be lifelong medical learners through their medical residency preparation, post-graduate programs and continuing medical education activities
Industry OtherConsumerSpecialties
Advertisement